Market Research

To obtain orthopaedic surgeon assessment of the Reverse HRS, the company commissioned third party market research surveys for the U.S. and the Top 5 largest E.U. Country markets (Spain, Italy, United Kingdom, France and Germany). To date, three independent market research studies totaling 309 Orthopaedic Surgeons (206 U.S. and 103 E.U.) have been completed. The first U.S. based study was completed in December 2011 and the second U.S. study and the initial E.U. report were completed in November 2014.

The study surveys included an Reverse HRS overview, a product description, key bench level testing results, Cadaveric study performance and a few brief videos. A series of general Hip Arthroplasty questions were asked in order to gain insight on the hip implant market and associated surgical trends. In addition, direct questions regarding the Reverse HRS were incorporated to secure product specific analysis and feedback. Selected Reverse HRS performance results are included below.

December 2011 U.S. Survey:

• 73% of U.S. surgeons believe that the Reverse HRS is an Improvement, a Significant Improvement or a Revolutionary Step Forward versus currently marketed designs.
• U.S. surgeons reported that the Reverse HRS could capture a U.S. market share of 29.1%.

November 2014 U.S. Survey:

• 83% of U.S. surgeons believe that the Reverse HRS is an Improvement, a Significant Improvement or a Revolutionary Step Forward versus currently marketed designs.
• U.S. surgeons reported that the Reverse HRS could capture a U.S. hip implant market share of 32.8%.
• U.S. surgeons reported that the Reverse HRS could capture 36.4% of their primary THA surgeries, 34.9% of their revisions and 23.4% of the fracture procedures in their practice.
• Based on U.S. surgeon responses, the Reverse HRS could capture a Metal on Poly (MoP) market share of 49.1%

November 2014 E.U. Survey:

• 88% of E.U. surgeons believe that the Reverse HRS is an Improvement, a Significant Improvement or a Revolutionary Step Forward versus currently marketed designs.
• E.U. surgeons reported that the Reverse HRS could capture a E.U. hip implant market share of 25.2%.
• E.U. surgeons reported that the Reverse HRS could capture 37.1% of their primary THA surgeries, 24.7% of their revisions and 27.6% of the fracture procedures in their practice.
• Based on E.U. surgeon responses, the Reverse HRS could capture a Metal on Poly (MoP) market share of 47.2%

In summary, the three independent U.S. and E.U. market research surveys, which included 309 orthopaedic surgeons, supported significant Reverse HRS market shares, global product acceptance, high THA and Revision procedure utilization and the potential patient treatment population was determined to be extensive.